The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, Young HA, Ching LM, Vogel SN.
Roberts ZJ, et al. Among authors: fitzgerald ka.
J Exp Med. 2007 Jul 9;204(7):1559-69. doi: 10.1084/jem.20061845. Epub 2007 Jun 11.
J Exp Med. 2007.
PMID: 17562815
Free PMC article.